In the rapidly expanding field of gene therapy, ensuring safety and efficacy remains a primary challenge. Neutralizing antibodies (NAb) against adeno-associated virus (AAV) capsids can impede the success of treatments.
This blog post explores strategies to overcome NAb challenges and introduces the iLite® AAV NAb platform for precise NAb measurement across different AAV serotypes in human and non-human primate (NHP) serum samples.